WellCare should be bought aggressively on any weakness, says Stifel Nicolaus Stifel believes that WellCare could report poor Q4 results and provide weak 2013 guidance. However, the firm thinks that short covering and purchases by longer term investors will boost the stock, and it maintains a $70 price target and Buy rating.
News For WCG From The Last 14 Days
Check below for free stories on WCG the last two weeks.
WellCare downgraded at Wedbush As noted earlier, Wedbush downgraded WellCare to Neutral from Outperform. The firm no longer sees the company as a takeover candidate, and it thinks that the company will need at least 2-3 years to turn itself around. Target to $55 from $70.